Amgen lung cancer combo shows survival gain in late-stage trial

Amgen lung cancer combo shows survival gain in late-stage trial
Amgen combo boosts survival

Late-stage trial results suggest Amgen may strengthen Imdelltra's commercial prospects in small cell lung cancer by pairing it with AstraZeneca's Imfinzi. The study shows the combination cuts the risk of death by 58% in patients with extensive-stage disease and extends median overall survival to 21.1 months from 12.7 months.

Highlights

  • Adding Amgen's Imdelltra to AstraZeneca's Imfinzi reduces risk of death by 58% and extends median survival to 21.1 months in late-stage small cell lung cancer.
  • Imdelltra posted $288 million in Q2 sales, up 115% year-over-year, and is projected to generate $627 million in global sales in 2025, nearing blockbuster status.
  • Trial results show survival benefit for the combination across all patient subgroups, including those with brain or liver metastases, addressing a major unmet need in the roughly 31,000 annual U.S. cases.

Trial results and treatment profile

As first reported by CNBC, full results released Saturday show that adding Amgen's immunotherapy Imdelltra to AstraZeneca's Imfinzi cuts the risk of death by 58% in patients with extensive-stage small cell lung cancer, a fast-growing form of the disease that has spread beyond the lung where it began.

The trial shows the drug combination extends median overall survival to 21.1 months, compared with 12.7 months for patients receiving Imfinzi alone. It tests the regimen as a maintenance therapy in patients whose cancer has not progressed after initial treatment with Imfinzi and chemotherapy.

Dr. Paul Burton, Amgen's chief medical officer, says the data have the potential to transform the standard of care for patients. He says the combination could help turn one of the most aggressive cancers into a more chronic disease for some patients.

Market potential and disease burden

The findings also point to a broader commercial opening for Imdelltra, which posts $288 million in second-quarter sales, up 115% from a year earlier. The drug already generates $627 million in global sales in 2025 and appears to be moving toward blockbuster status, the industry term for annual sales of at least $1 billion.

Lead trial investigator Dr. Jacob Sands, associate chief of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, says small cell lung cancer remains difficult to treat because the disease often returns or progresses within months even when chemotherapy initially works. He says immunotherapy has delivered years of control for a small subset of patients, but most have not seen durable benefit, underscoring demand for improved options.

There are roughly 31,000 new small cell lung cancer cases in the U.S. each year, and an estimated 60% to 70% of those patients are diagnosed with extensive-stage disease. Sands says the trial's benefit appears across patient subgroups, including those whose cancer has spread to the brain or liver, where outcomes are usually worse.

Our earlier article on AstraZeneca’s AI drug discovery partnership with insitro explained how the company is expanding the use of artificial intelligence in early-stage research. We noted that the multi-year deal targets MASH and cardiomyopathies, with insitro’s “Virtual Human” platform helping identify and validate biological targets before AstraZeneca takes them into clinical development.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.